Industry News
Biotechnology Industry News
More than 100 marchers took to…
More than 100 marchers took to Capitol Hill on Wednesday after carrying a coffin to the FDA in a symbolic protest highlighting lives they say could be lost to regulatory delays affecting a group of
For children with Dravet syndrome,…
For children with Dravet syndrome, a rare, severe genetic disease characterized by fever-related seizures and intellectual disability, developmental delays begin after the first few years of normal development. Stoke Therapeutics is developing a drug designed
Crossbow Therapeutics has…
Crossbow Therapeutics has successfully hit a $77 million series B round, which the biotech will use to fund a trial of its lead T-cell engager (TCE) and fill its quiver with more T-Bolts.
Aspen Neuroscience’s stem cell…
Aspen Neuroscience’s stem cell therapy improved Parkinson’s disease symptoms for all eight treated patients after one year, with the San Diego biotech now planning for a pivotal phase 3 trial later this year.
Health authorities in the U.S. are…
Health authorities in the U.S. are continuing their move away from animal testing in drug development, with the FDA signaling an openness to new approaches that haven’t been validated.
Since raising a mind-boggling $1…
Since raising a mind-boggling $1 billion in 2024, AI-driven Xaira Therapeutics has remained largely silent on where that money is being put to work. Last week, the company’s Chief Operating Officer, Jeff Jonker, opened up
The pharma is transitioning…
The pharma is transitioning operations and management of its New York City JLABS space to the site owner, the New York Genome Center (NYGC).
Bicycle Therapeutics is letting…
Bicycle Therapeutics is letting more air out of its operations, with plans to deflate its employee count by about 30% and shelve its lead anti-cancer drug conjugate.
After delaying its review, the FDA…
After delaying its review, the FDA has rejected Aldeyra Therapeutics’ experimental dry eye disease treatment for the third time.
A phase 2 study of Pfizer’s…
A phase 2 study of Pfizer’s atirmociclib has hit its primary endpoint, providing evidence that the CDK4 inhibitor improves progression-free survival in second-line metastatic breast cancer. But the Big Pharma is already looking past the
BioVie is eyeing a $19.7 million…
BioVie is eyeing a $19.7 million IPO for a spinout focused on bringing a new formulation of an approved low blood pressure drug to market as a potential treatment for liver disease.
Swiss pharma Roche is staying in…
Swiss pharma Roche is staying in lockstep with Eli Lilly, expanding its AI offerings and Nvidia partnership shortly after the latter drugmaker unveiled an Nvidia supercomputer.
Astellas is pulling out of its…
Astellas is pulling out of its $1.6 billion biobucks partnership with CytomX six years after the two companies set out to explore T-cell-engaging bispecifics for the treatment of solid tumors.
Structure Therapeutics has touted…
Structure Therapeutics has touted the 16% weight loss seen by aleniglipron as the best results yet for an oral GLP-1 drug, as the obesity biotech readies the candidate for phase 3.
R1 Therapeutics is debuting with…
R1 Therapeutics is debuting with an oversubscribed $77.5 million Series A financing aimed at advancing its first-in-class therapy for hyperphosphatemia in patients on dialysis with chronic kidney disease (CKD).
In a 14-month follow-up, Sana…
In a 14-month follow-up, Sana Biotechnology has found that its investigational allogeneic cell therapy continued to produce insulin for one patient with Type 1 diabetes, with no safety concerns reported.
Inovio Pharmaceuticals has laid…
Inovio Pharmaceuticals has laid off staff and prioritized programs to focus on its lead rare disease candidate, which is already facing some pushback from the FDA early in its approval review.
Immutep and the Australian…
Immutep and the Australian biotech’s investors have been caught off guard by the unexpected failure of its LAG-3 candidate in a phase 3 study.
Years after BioNTech’s CEO Uğur…
Years after BioNTech’s CEO Uğur Şahin, M.D. and chief medical officer Özlem Türeci, M.D., spearheaded the company through the roaring commercial success of Pfizer-partnered COVID-19 vaccine Comirnaty, the duo is preparing to take their hands
Artificial intelligence (AI) now…
Artificial intelligence (AI) now features prominently in boardroom and executive discussions across the life sciences industry. The attention is understandable: AI has the potential to fundamentally reshape how companies discover, develop and deliver new therapies.